With a market cap of $143.3 billion, Danaher Corporation (DHR) is a leading global life sciences and diagnostics innovator that combines advanced science, technology, and industry-leading businesses to help customers address complex scientific and clinical challenges and accelerate innovations from discovery to delivery. With approximately 60,000 associates worldwide, the company leverages its Danaher Business System and operational excellence to enable faster, more accurate diagnoses and support the development and delivery of life-changing therapies.
Shares of the industrial and medical device maker have underperformed the broader market over the past 52 weeks. DHR stock has dropped 2.5% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 20.6%. Moreover, shares of the company are down 10.9% on a YTD basis, compared to SPX's 13.9% gain.
Looking closer, shares of the Washington, the District Of Columbia-based company have lagged behind the State Street Health Care Select Sector SPDR ETF's (XLV) 25.5% return over the past 52 weeks and a 8.6% YTD rise.
Danaher’s shares tumbled nearly 11% on Jul. 21 after the company cut its 2026 core revenue growth outlook to 3% - 4%, mainly due to weaker respiratory-testing revenue. Investor concerns were amplified by a weaker-than-expected biotechnology revenue performance, as more than $100 million of bioprocessing revenue was pushed into next year because of shipment timing, despite bioprocessing orders rising by mid-teens.
Although Q2 2026 adjusted EPS of $1.94 beat the estimate and full-year adjusted EPS guidance was raised to $8.45 - $8.60, the revenue outlook cut and biotech weakness overshadowed the profit beat.
For the fiscal year ending in December 2026, analysts expect Danaher's adjusted EPS to grow 9.4% year-over-year to $8.53. The company's earnings surprise history is promising. It beat the consensus estimates in each of the last four quarters.
Among the 24 analysts covering the stock, the consensus rating is a “Strong Buy.” That’s based on 17 “Strong Buy” ratings, two “Moderate Buys,” and five “Holds.”
This configuration is slightly more bullish than three months ago, with 16 “Strong Buy” ratings on the stock.
On Jul. 22, TD Cowen cut Danaher’s price target to $236 while maintaining a “Buy” rating.
The mean price target of $223.09 represents a premium of 9.4% to DHR's current levels. The Street-high price target of $310, implies a potential upside of 52%.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
/A%20hand%20holding%20a%20phone%20with%20the%20Reddit%20logo_%20Mamun_Sheikh%20via%20Shutterstock_.jpg)
